Alpha Tau Medical Ltd Cl A (DRTS) Stock Price, Quote & News

Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 577 4115

Website: www.alphatau.com

Address:

Kiryat HaMada St. 5, Jerusalem, Israel

DJTEM Aug. 19 at 3:31 PM

$SLS Remember that the hide gem is $DRTS. An Israeli company that will make lot of milionaires. Alex

3 · Reply

CapitalMonk Aug. 19 at 3:19 PM

$DRTS Price: $14.52 (+1.82%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±2.86% RSI: 77.0 | Momentum: Strong Momentum Volume: -42.0% vs avg Volatility: 3.89% Support: $10.96 | Resistance: $14.75 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai

0 · Reply

Sirsoul Aug. 19 at 3:17 PM

$DRTS One if my favorite stocks currently. Still kicking myself for not having bought more shares at $7. Regardless I still plan on adding at this price and beyond.

0 · Reply

JohnStocksNY Aug. 19 at 2:51 PM

$DRTS What exciting news for the cancer space! Let’s get that DRTS with Keytruda trial going!

0 · Reply

kareem1988 Aug. 19 at 2:37 PM

Great post on Reddit on why $DRTS looks massively underpriced next to Moderna's Keytruda combo pop today https://www.reddit.com/r/TheRaceTo10Million/s/6m8MddbbNO $MRK $MRNA

1 · Reply

kareem1988 Aug. 19 at 2:22 PM

$DRTS 14.20 flipped from resistance to support and buyers keep defending it on every dip, feels like the stock wants higher from here.

0 · Reply

Yadabadabingbong Aug. 19 at 1:16 PM

$DRTS with Moderna curing cancer we may all be screwed :0

3 · Reply

Jordan3333 Aug. 19 at 12:59 PM

$DRTS So many great things going on at $DRTS each one of them is is worth 10 times alpha’s market cap. Today we were reminded of this, MRNA added 20 billion dollars of market cap on their Keytruda announcement, $DRTS is waiting for an IDE for approval that should be in the very near future, after the company presented results of their study showing 100% response rate, should bring the $DRTS to several billions market cap

0 · Reply

Jessypenny Aug. 19 at 12:41 PM

$MRNA is up 90% in premarket after combination trial with $MRK Keytruda was announced. $DRTS had 100% ORR in the Hadassah combination trial with Keytruda and should receive IDE in the near future.

1 · Reply

Jessypenny Aug. 19 at 12:31 PM

$DRTS Alpha Tau is discussing U.S. trial expansion with the FDA. Look at what $MRK Keytruda combination milestones did to $MRNA’s valuation. combination therapies in oncology carry serious upside potential. https://finance.yahoo.com/healthcare/articles/merck-moderna-announce-phase-3-104500208.html

1 · Reply

Alpha Tau price target raised to $16 from $15 at H.C. Wainwright

2026-08-10T20:20:38.000Z - 8 days ago

Alpha Tau reports Q2 EPS (25c), consensus (14c)

Aug 10, 2026, 8:00 AM EDT - 9 days ago

Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

2026-07-21T13:05:21.000Z - 4 weeks ago

Alpha Tau reports Alpha DaRT combination study results

Jul 21, 2026, 8:30 AM EDT - 4 weeks ago

Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success

2026-07-15T13:15:30.000Z - 5 weeks ago

Alpha Tau treats first patient in ADMIRE study for recurrent skin cancer

Jul 15, 2026, 8:30 AM EDT - 5 weeks ago

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center

2026-06-23T16:01:28.000Z - 2 months ago

Alpha Tau treats first glioblastoma patient in Israel with Alpha DaRT

Jun 23, 2026, 8:30 AM EDT - 2 months ago

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

2026-06-11T13:17:41.000Z - 2 months ago

Alpha Tau gets FDA clearance to complete enrollment in REGAIN trial

Jun 11, 2026, 8:30 AM EDT - 2 months ago

Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control

2026-06-04T09:11:16.000Z - 2 months ago

Alpha Tau price target raised to $17 from $15 at Barclays

2026-06-03T14:53:02.000Z - 2 months ago

Alpha Tau, Tolmar announce strategic collaboration agreement

Jun 3, 2026, 8:30 AM EDT - 2 months ago

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

2026-06-01T13:43:39.000Z - 2 months ago

Alpha Tau reports positive survival data from pancreatic cancer study

Jun 1, 2026, 9:00 AM EDT - 2 months ago

Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting

May 28, 2026, 9:00 AM EDT - 2 months ago

Alpha Tau Medical Transcript: Lytham Partners Spring 2026 Investor Conference

2026-05-28T09:27:08.000Z - 2 months ago

Alpha Tau initiated with an Overweight at Barclays

2026-05-19T11:07:23.000Z - 3 months ago

Alpha Tau price target raised to $8 from $5 at Piper Sandler

2026-05-18T20:08:09.000Z - 3 months ago

Alpha Tau reports Q1 EPS (12c), consensus (12c)

May 18, 2026, 4:01 PM EDT - 3 months ago

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

May 18, 2026, 4:00 PM EDT - 3 months ago

Alpha Tau Medical Earnings release: Q1 2026

May 18, 2026, 8:30 AM EDT - 3 months ago

Alpha Tau to Participate in May Investor Conferences

May 15, 2026, 7:00 AM EDT - 3 months ago

Alpha Tau Medical Slides: Investor presentation

2026-05-12T15:35:38.000Z - 3 months ago

Alpha Tau price target raised to $14 from $12 at Ladenburg

2026-05-12T10:48:07.000Z - 3 months ago

Alpha Tau price target raised to $15 from $12 at H.C. Wainwright

May 11, 2026, 8:30 AM EDT - 3 months ago

Alpha Tau Medical Transcript: Study result

May 11, 2026, 8:30 AM EDT - 3 months ago

Alpha Tau Medical Press release: Study result

May 11, 2026, 8:30 AM EDT - 3 months ago

Alpha Tau Medical Slides: Study result

2026-05-11T12:24:42.000Z - 3 months ago

Alpha Tau announces interim data from REGAIN trial

May 11, 2026, 7:00 AM EDT - 3 months ago

Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET

2026-05-08T15:18:00.000Z - 3 months ago

Alpha Tau completes enrollment in ReSTART trial

May 8, 2026, 9:10 AM EDT - 3 months ago

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

May 8, 2026, 9:00 AM EDT - 3 months ago

Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma

2026-05-07T18:29:44.000Z - 3 months ago

Alpha Tau treats first patient with Alpha DaRT in Italy

May 7, 2026, 9:00 AM EDT - 3 months ago

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona's Pancreas Institute

May 5, 2026, 9:14 AM EDT - 3 months ago

Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab

May 4, 2026, 9:17 AM EDT - 3 months ago

Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026

Apr 29, 2026, 9:00 AM EDT - 4 months ago

Medical University of South Carolina and Revival Healthcare Capital Announce Five-Year Strategic Innovation Partnership

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Alpha Tau Medical Registration statement: Registration filing

Apr 27, 2026, 9:01 AM EDT - 4 months ago

Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies

Apr 23, 2026, 9:02 AM EDT - 4 months ago

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)

Apr 23, 2026, 9:01 AM EDT - 4 months ago

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial

Mar 31, 2026, 9:15 AM EDT - 5 months ago

Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026

Mar 18, 2026, 10:00 AM EDT - 5 months ago

Alpha Tau Medical Transcript: Sidoti March Small-Cap Virtual Conference

Mar 16, 2026, 10:02 AM EDT - 5 months ago

Alpha Tau to Present at Sidoti March Virtual Small Cap Conference

Mar 10, 2026, 7:00 AM EDT - 5 months ago

Alpha Tau Medical Slides: Investor presentation

Mar 9, 2026, 5:00 PM EDT - 5 months ago

Alpha Tau Medical Annual report: Q4 2025

Mar 9, 2026, 5:00 PM EDT - 5 months ago

Alpha Tau Medical Earnings release: Q4 2025

Mar 9, 2026, 4:02 PM EDT - 5 months ago

Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update

Mar 9, 2026, 7:00 AM EDT - 5 months ago

Alpha Tau Medical Slides: Investor presentation

Feb 24, 2026, 8:51 PM EST - 6 months ago

HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT

Feb 24, 2026, 9:00 AM EST - 6 months ago

Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer

Feb 3, 2026, 12:37 PM EST - 7 months ago

Altamirano PLLC Issues Investor Notice on Inspired Healthcare Capital (IHC) Chapter 11 Bankruptcy Filing

Jan 29, 2026, 9:00 AM EST - 7 months ago

Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead

Jan 15, 2026, 4:00 PM EST - 7 months ago

Alpha Tau Medical Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

Jan 15, 2026, 2:15 PM EST - 7 months ago

Alpha Tau Medical Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 9:00 AM EST - 8 months ago

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study

Jan 5, 2026, 9:00 AM EST - 8 months ago

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

Dec 10, 2025, 11:30 AM EST - 9 months ago

Alpha Tau Medical Transcript: Sidoti's Year End Virtual Investor Conference

Dec 9, 2025, 9:00 AM EST - 9 months ago

Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University

Nov 21, 2025, 7:00 AM EST - 9 months ago

Alpha Tau Medical Slides: Investor presentation

Nov 20, 2025, 4:05 PM EST - 9 months ago

Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 20, 2025, 12:00 AM EST - 9 months ago

Alpha Tau Medical Earnings release: Q3 2025

Nov 11, 2025, 8:30 AM EST - 10 months ago

Alpha Tau to Participate at Jefferies Global Healthcare Conference in London

Oct 21, 2025, 8:30 AM EDT - 10 months ago

Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness

Oct 17, 2025, 10:04 AM EDT - 10 months ago

Altamirano PLLC Issues Notice to Inspired Healthcare Capital (IHC) Investors on Recovery Options

Sep 30, 2025, 12:30 PM EDT - 11 months ago

Alpha Tau Medical Transcript: Lytham Partners Fall 2025 Investor Conference

Sep 2, 2025, 8:30 AM EDT - 1 year ago

Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial

Aug 27, 2025, 8:30 AM EDT - 1 year ago

Alpha Tau to Participate in Five September Investor Conferences

Aug 11, 2025, 4:02 PM EDT - 1 year ago

Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 10, 2025, 6:00 PM EDT - 1 year ago

Alpha Tau Medical Earnings release: Q2 2025

Jul 25, 2025, 9:04 AM EDT - 1 year ago

Revival Healthcare Capital Announces Strategic Partnership to Accelerate External Innovation in Robotics With up to $458 Million Joint Investment With Olympus Into Co-Founded New Company Swan EndoSurgical

Jun 23, 2025, 8:00 AM EDT - 1 year ago

Alpha Tau Medical Registration statement: Registration Filing

May 19, 2025, 4:01 PM EDT - 1 year ago

Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 19, 2025, 4:00 PM EDT - 1 year ago

Alpha Tau Medical Earnings release: Q1 2025

May 12, 2025, 4:01 PM EDT - 1 year ago

Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors

Apr 28, 2025, 9:00 AM EDT - 1 year ago

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

ORMP

Apr 28, 2025, 9:00 AM EDT - 1 year ago

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

ORMP

Apr 2, 2025, 8:30 AM EDT - 1 year ago

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

Mar 19, 2025, 11:30 AM EDT - 1 year ago

Alpha Tau Medical Transcript: Sidoti Small-Cap Virtual Conference

Mar 12, 2025, 4:02 PM EDT - 1 year ago

Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

Mar 12, 2025, 4:00 PM EDT - 1 year ago

Alpha Tau Medical Earnings release: Q4 2024

Mar 12, 2025, 4:00 PM EDT - 1 year ago

Alpha Tau Medical Annual report: Q4 2024

Feb 24, 2025, 8:30 AM EST - 1 year ago

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

Jan 27, 2025, 9:00 AM EST - 1 year ago

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

Jan 27, 2025, 8:00 AM EST - 1 year ago

Alpha Tau Medical Transcript: R&D Day 2025

Jan 27, 2025, 8:00 AM EST - 1 year ago

Alpha Tau Medical Slides: FY 2025

Jan 16, 2025, 12:45 PM EST - 1 year ago

Alpha Tau Medical Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Dec 18, 2024, 8:30 AM EST - 1 year ago

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

Dec 17, 2024, 9:00 AM EST - 1 year ago

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

Dec 11, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 6, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium

Nov 18, 2024, 6:00 PM EST - 1 year ago

Alpha Tau Medical Earnings release: Q3 2024

Nov 13, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Participate in Citi's 2024 Global Healthcare Conference and Piper Sandler's 36th Annual Healthcare Conference

DJTEM Aug. 19 at 3:31 PM

$SLS Remember that the hide gem is $DRTS. An Israeli company that will make lot of milionaires. Alex

3 · Reply

CapitalMonk Aug. 19 at 3:19 PM

0 · Reply

Sirsoul Aug. 19 at 3:17 PM

$DRTS One if my favorite stocks currently. Still kicking myself for not having bought more shares at $7. Regardless I still plan on adding at this price and beyond.

0 · Reply

JohnStocksNY Aug. 19 at 2:51 PM

$DRTS What exciting news for the cancer space! Let’s get that DRTS with Keytruda trial going!

0 · Reply

kareem1988 Aug. 19 at 2:37 PM

Great post on Reddit on why $DRTS looks massively underpriced next to Moderna's Keytruda combo pop today https://www.reddit.com/r/TheRaceTo10Million/s/6m8MddbbNO $MRK $MRNA

1 · Reply

kareem1988 Aug. 19 at 2:22 PM

$DRTS 14.20 flipped from resistance to support and buyers keep defending it on every dip, feels like the stock wants higher from here.

0 · Reply

Yadabadabingbong Aug. 19 at 1:16 PM

$DRTS with Moderna curing cancer we may all be screwed :0

3 · Reply

Jordan3333 Aug. 19 at 12:59 PM

0 · Reply

Jessypenny Aug. 19 at 12:41 PM

$MRNA is up 90% in premarket after combination trial with $MRK Keytruda was announced. $DRTS had 100% ORR in the Hadassah combination trial with Keytruda and should receive IDE in the near future.

1 · Reply

Jessypenny Aug. 19 at 12:31 PM

1 · Reply

kareem1988 Aug. 19 at 8:30 AM

$DRTS Catching a breather above $14, Holding onto most of the gains after a strong run. looks like buyers aren't in a rush to exit. Steady accumulation.

1 · Reply

JohnStocksNY Aug. 19 at 7:44 AM

$DRTS Those clips from the CEO Interview are amazing!

2 · Reply

wasianinvasion Aug. 19 at 5:32 AM

$DRTS Bought 2000 warrants today

1 · Reply

Stock_Catcher Aug. 19 at 1:16 AM

Wealthy Wednesday Watchlist - Daily Charts $ONDS $SLS $DRTS $BULL $AMC

1 · Reply

Dutchholdem Aug. 18 at 7:56 PM

$ORMP seems it has attracted some bigger buyer last 2 days. Current $DRTS position only of ORMP accounts for a shareprice of around 5.60-5.70 dollar shareprice for ORMP, currently just below 4.80. Add in other positions and it's still discounted.

0 · Reply

Merlintrader Aug. 18 at 3:53 PM

$DRTS Alpha Tau's Alpha DaRT delivers alpha radiation directly inside solid tumours, with recurrent glioblastoma and pancreatic cancer among the programmes and ReSTART the central US approval path. The market has already travelled a long way: up 185.9% year to date to the August 17 close, on 92,478,154 shares for a market value near 1.31 billion dollars. Insiders hold about 20.3%. Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/alpha-tau-stock-hub/

0 · Reply

Jessypenny Aug. 18 at 12:38 PM

@AlphaTauInsight over on X came out with a series of short translated videos of $DRTS CEO Uzi Sofer interviewed on a podcast. “Alpha Tau will be the Standard of Care all over the world” https://x.com/AlphaTauInsight/status/2089307914242535779?s=20 https://x.com/AlphaTauInsight/status/2089342597361754184?s=20 https://x.com/AlphaTauInsight/status/2089661506019303487?s=20

3 · Reply

Wilsonism Aug. 18 at 9:53 AM

$DRTS chart is looking incredibly clean right now. The 50-day and 200-day moving averages are stacked perfectly, showing a solid long term uptrend. RSI at 55.1 plenty of room before things get overheated. MACD is positive, so the momentum is definitely on our side.

3 · Reply

WallStWireAds Aug. 17 at 11:47 PM

$DRTS

2 · Reply

HugZnotDrugZz Aug. 17 at 10:15 PM

$HOVR $ASTS $DRTS Sorry but you need to own all 3. ***Follow Freddy

2 · Reply

Dutchholdem Aug. 17 at 2:16 PM

$DRTS had to add at 13.9. nice to do so and having kept some ammunition from last Friday. Did not expect it today though....

2 · Reply

Jessypenny Aug. 17 at 11:20 AM

$DRTS NICE!!!

6 · Reply

Market Cap	1.28B
Revenue (ttm)	0.00
Net Income (ttm)	-42.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.15

Volume	374,700
Avg Vol	679,884
Day's Range	N/A - N/A
Shares Out	90.33M
Stochastic %K	75%
Beta	1.17
Analysts	Strong Sell
Price Target	$13.75